Study Comparing Two Vaccine Combinations with Immunotherapy for Treatable Pancreatic Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials ID:NCT06782932
This clinical trial is testing two different vaccine combinations, along with immunotherapy, to find the safest and most effective treatment for patients with pancreatic cancer that can be surgically removed.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The study aims to find the best dose of a new drug, AGEN2373, when used with another drug, balstilimab, and a vaccine called Pancreatic GVAX. It will also test the safety and effectiveness of these drugs and vaccines in two groups: one receiving GVAX and the other receiving a different vaccine, mKRASvax, for patients with pancreatic cancer that can be surgically removed.
Eligibility Criteria
Inclusion Criteria
- Have a new diagnosis of pancreatic cancer confirmed by a biopsy.
- The tumor must be considered removable by surgery.
- Agree to have a tumor biopsy.
- Be in good overall health, with an activity level that allows for light work or better.
- Have good organ and bone marrow function based on specific lab tests.
- Women who can have children must have a negative pregnancy test.
- Both men and women must agree to use effective birth control during the study.
Exclusion Criteria
- Have received any treatment for pancreatic cancer or any previous cancer immunotherapy.
- Have another cancer that could affect the study's results.
- Have uncontrolled health issues like infections, heart problems, or mental health conditions that could interfere with the study.
- Have an active autoimmune disease.
- Are taking high doses of steroids or other immune-suppressing drugs recently.
- Have an active infection needing treatment.
- Have a history of HIV, hepatitis B or C, or active tuberculosis.
- Have lung diseases like COPD or asthma that require medication.
- Have had a stem cell or organ transplant.
- Have had major surgery recently.
- Have received a live vaccine recently.
- Have had severe allergic reactions to monoclonal antibodies.
- Are participating in another clinical study.
- Are pregnant or breastfeeding.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | 21287 | Baltimore | Maryland |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.
